U.S. FDA Talks Drug Safety With China, But Visas Still Elusive
This article was originally published in PharmAsia News
The U.S. agency is finding itself unable to place more inspectors in China even as senior official Howard Sklamberg visits Beijing.
You may also be interested in...
FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production
FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.
U.S. FDA Set To Strengthen Inspections Of Chinese Drugmakers, Search For Adulterants In Aftermath Of Heparin Deaths – CDER Official
BEIJING - As U.S. FDA leaders select inspectors to deploy across three new offices being set up in China, the organization is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drugmakers that export to the U.S
Virtual kick-off meetings may be necessary, but preparations continue in anticipation of the formal talks to reauthorize the prescription drug, generic drug and biosimilar user fee programs.